Abstract: The present invention concerns novel compounds of the general formula; ##STR1## wherein R.sub.1 is halogen or hydrogen and R.sub.2 is halogen; X is either oxygen, sulfor or methyleneR.sub.3 and R.sub.4 are the same or different and selected from hydrogen and lower alkyl;n is 2 or 3;A is selected from the following pyrimidyl or pyridyl groups ##STR2## wherein R.sub.5 is selected from hydrogen, lower alkyl or halogen; R.sub.6 and R.sub.7 are the same or different and selected from hydrogen, halogen, lower alkyl, electron donor groups such as lower alkoxy or hydroxy, electron acceptor groups such as cyano, nitro, trifluoromethyl, COOR.sub.8, CONR.sub.9 R.sub.10 or CO-B;wherein R.sub.8 is hydrogen or lower alkyl;R.sub.9 and R.sub.10 are the same or different and selected from hydrogen, lower alkyl and cycloalkyl;B is selected from ##STR3## wherein m is 1, 2, 3 or 4. R.sub.11 is selected from hydrogen or lower alkyl, and the pharmacologically active salts thereof.

Abstract: A compound having the formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein all the symbols are defined in the specification; having valuable pharmaceutical properties, useful for the treatment of mental disorders, such as psychoses, depression and anxiety.

Abstract: A series of 1-piperazinecarboxamide derivatives of the following formula: ##STR1## The compounds of the present invention are neuropharmacological agents intended for the treatment of mental disorders, such as psychoses and depression.

Abstract: Novel compounds of formula (I), wherein R.sub.1 is selected from hydrogen, halogen; or trifluoromethyl; X is oxygen or sulfur; R.sub.2 and R.sub.3 are the same or different and selected from hydrogen or lower alkyl; m is 2 or 3; Y is oxygen or sulphur; Z is selected from: --NR.sub.4 R.sub.5, formulae (II), (III) or (IV), wherein R.sub.4 and R.sub.5 are the same or different and selected from hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy-alkyl, alkoxyalkyl or alkanoyloxyalkyl, phenyl or phenyl-alkyl, wherein the phenyl groups may be unsubstituted or monosubstituted with halogen or CF.sub.3 ; n is 0, 1, 2 or 3; R.sub.6 and R.sub.7 are the same or different and selected from hydrogen, lower alkyl, hydroxy, lower alkoxy or lower alkanoyloxy; p is 2 or 3; R.sub.8 and R.sub.9 are the same or different and selected from hydrogen or lower alkyl; R.sub.10 is hydrogen, lower alkyl or lower alkanoyl. The new compounds can be used for treating mental disorders.

Abstract: Novel compounds of the formula ##STR1## wherein R' is selected from the group consisting of alkyl straight or branch chained having from 2 to 10 carbon atoms, cycloalkyl having from 3 to 8 carbon atoms, aralkyl having from 7 to 9 carbon atoms, phenyl and substituted phenyl wherein the substituents of the substituted phenyl are selected from the group consisting of one to three F, Cl, Br, lower alkyl having from 1 to 5 carbon atoms, lower alkoxy having from 1 to 5 carbon atoms, alkylenedioxy having from 1 to 3 carbon atoms, --CF.sub.3 and --CN and pharmaceutically acceptable salts thereof which have been found to have utility for therapeutic treatment of mental disorders by reducing anti-aggressive behavior and a process for making the compounds.

Abstract: Compounds having the general formula ##STR1## as herein defined and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions containing said compounds. Methods of treatment of humans and animals by such compounds and compositions.

Abstract: Compounds having the general formula ##STR1## as herein defined and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions containing said compounds. Methods of treatment of humans and animals by such compounds and compositions.

Abstract: Aryl ethers of N-alkyl-piperdines having the formula ##STR1## wherein R.sub.1 represents hydrogen, halogen including F, Cl and Br, a lower alkanoyl group (e.g. alkanoyl of up to five carbon atoms), an alkenyl group (having three to five carbon atoms) or phenoxy, R.sub.2 represents hydrogen, halogen including F, Cl and Br, --CN group, a lower alkoxy group (e.g. alkoxy of up to five carbon atoms), a lower alkanoyl group (e.g. alkanoyl of up to five carbon atoms), an alkenyloxy or alkynyloxy group (having three to five carbon atoms) or a lower alkoxycarbonyl group (e.g. alkoxycarbonyl of up to five carbon atoms), R.sub.3 and R.sub.4 independently represent hydrogen, halogen including F, Cl and Br, a --CF.sub.3 group, a lower alkyl group (e.g. alkyl of up to five carbon atoms) or a lower alkoxy group (e.g. alkoxy of up to five carbon atoms), R.sub.5 represents hydrogen or an acyl group with 2-19 carbon atoms and n=3 or 4, and pharmaceutically acceptable acid addition salts.

Abstract: Compounds having the general formula ##STR1## as herein defined and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions containing said compounds. Methods of treatment of humans and animals by such compounds and compositions.

Abstract: Novel alkyl 1-(hydroxyalkyl)piperidines and acid addition salts thereof, useful as inhibitors of dental plaque and therefore also useful against dental caries and periodontitis, are disclosed. Methods of making same, orally-acceptable compositions thereof, a method of treating therewith, and important and novel intermediates for the production thereof are also disclosed.

Abstract: 2,3,4,7,8,9-Substituted octahydropyrazinopyrimidinones and acid addition salts thereof. A process for the preparation of said compounds. A pharmaceutical composition comprising such a compound and a conventional carrier. A process for the preparation of said composition. Method of medical treatment of human beings and animals using such compounds.